CVS Health (NYSE:CVS) Given New $104.00 Price Target at Leerink Partners

CVS Health (NYSE:CVS) had its price target cut by investment analysts at Leerink Partners from $112.00 to $104.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the pharmacy operator’s stock. Leerink Partners‘s price objective indicates a potential upside of 29.49% from the company’s current price.

Several other equities research analysts have also commented on CVS. BMO Capital Markets set a $112.00 price target on shares of CVS Health in a report on Wednesday, September 9th. UBS Group set a $110.00 price objective on CVS Health in a research note on Wednesday. Raymond James Financial reissued an “outperform” rating and issued a $120.00 price objective on shares of CVS Health in a report on Wednesday. Evercore restated an “outperform” rating on shares of CVS Health in a research note on Wednesday. Finally, Barclays dropped their target price on CVS Health from $108.00 to $107.00 and set an “overweight” rating on the stock in a report on Thursday. Twenty-two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $109.08.

CVS Health Stock Performance

NYSE:CVS traded up $0.35 during midday trading on Thursday, hitting $80.31. The company’s stock had a trading volume of 12,992,792 shares, compared to its average volume of 8,482,670. CVS Health has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market cap of $102.72 billion, a P/E ratio of 21.23, a P/E/G ratio of 0.85 and a beta of 0.58. The firm’s 50 day moving average is $90.82 and its 200-day moving average is $88.86.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, beating the consensus estimate of $1.65 by $0.44. The business had revenue of $108.40 billion for the quarter, compared to the consensus estimate of $104.72 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.60 EPS. Equities analysts anticipate that CVS Health will post 8.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CVS. Kilter Group LLC purchased a new position in CVS Health during the second quarter worth approximately $27,000. J.Safra Asset Management Corp purchased a new stake in shares of CVS Health in the second quarter valued at approximately $30,000. Beaird Harris Wealth Management LLC raised its stake in shares of CVS Health by 201.0% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 195 shares during the period. Timbuktu Capital Management LLC acquired a new position in shares of CVS Health during the 2nd quarter worth approximately $31,000. Finally, Dunhill Financial LLC purchased a new position in shares of CVS Health during the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported third-quarter adjusted earnings of $2.09 per share, above the roughly $1.65 consensus, while revenue rose 5.4% year over year to $108.4 billion. Management also raised its 2026 adjusted EPS outlook to at least $8.20 and operating cash flow guidance to at least $15.5 billion. Read More.
• Neutral Sentiment: The company plans to separate its retail pharmacy business from Aetna, Caremark and related healthcare operations, aiming to create two publicly traded companies by the first half of 2028. The separation could let each business focus on its own operations, but the potential value for shareholders will depend on how it is structured and executed. Read More.
• Negative Sentiment: The breakup announcement has overshadowed the earnings beat. Investors may be concerned about the execution risks of separating the businesses, including how debt and costs will be allocated and whether the companies can maintain the benefits of their existing integration. Read More.

CVS Health Company Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.